Moreover, the ester prodrug 21b of compound 21a could reduce the viability of AML cells by downregulating MYC and upregulating RARA, which was consistent with previous reports on the anticancer effect of pharmacological FTO inhibition [37,39]. The gene discussed is FTO; the disease is acute myeloid leukemia.